产品
编 号：F292079
分子式：(C10H13N4O8P)x.(C9H14N3O8P)x
分子式：(C10H13N4O8P)x.(C9H14N3O8P)x
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 24939-03-5
产品详情
生物活性：
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
体内研究：
Polyinosinic-polycytidylic acid (2.5-10 mg/mL, Stereotaxic injection, single dose) 在脑黑质和背外侧纹状体中诱导持续的炎症反应。Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) 降低小鼠的肺肿瘤生长。Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) 在 MCAO 模型小鼠中通过 TLR3 下调TLR4/MyD88 信号通路发挥脑缺血再灌注损伤的治疗作用。Animal Model:lung tumor-bearing mice
Dosage:10 μg/mouse
Administration:Intraperitoneal injection (i.p.)
Result:Induced a significant decrease in the growth of pulmonary metastases in tumor-bearing mice.Reduced the amount of lung foci to ≈ 40%.Significantly increased BAL fluid cell numbers. Increased the level of INF-γ and IL-17A, decreased the levels of IL-13.Increased TLR3 expression.
Animal Model:Middle cerebral artery occlusion (MCAO) model mice
Dosage:1.25 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Reduced focal cerebral I/R injury.Increased the expression of Bcl2, Hsp27, and Hsp70, decreased Bax expression, and reduced cellular degeneration and apoptosis.Protected against cerebral ischemia and conferred protection against cerebral I/R injury through the downregulation of TLR4 signaling via TLR3.
体外研究：
Polyinosinic-polycytidylic acid (0.5-5 μg/mL, 3-24 h) 呈现剂量和时间依赖性增加诱导永生化气道上皮细胞的细胞旁通透性。Polyinosinic-polycytidylic acid (5 μg/mL, 24 h) 对 16HBE14o- 细胞没有细胞毒性。Polyinosinic-polycytidylic acid (5 μg/mL, 6 h) 在 16HBE14o- 细胞中诱导上皮顶端连接复合体和紧密连接的破坏。
Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis.
体内研究：
Polyinosinic-polycytidylic acid (2.5-10 mg/mL, Stereotaxic injection, single dose) 在脑黑质和背外侧纹状体中诱导持续的炎症反应。Polyinosinic-polycytidylic acid (10 μg/mouse, Intraperitoneal injection, single dose) 降低小鼠的肺肿瘤生长。Polyinosinic-polycytidylic acid (1.25 mg/kg, Intraperitoneal injection, single dose) 在 MCAO 模型小鼠中通过 TLR3 下调TLR4/MyD88 信号通路发挥脑缺血再灌注损伤的治疗作用。Animal Model:lung tumor-bearing mice
Dosage:10 μg/mouse
Administration:Intraperitoneal injection (i.p.)
Result:Induced a significant decrease in the growth of pulmonary metastases in tumor-bearing mice.Reduced the amount of lung foci to ≈ 40%.Significantly increased BAL fluid cell numbers. Increased the level of INF-γ and IL-17A, decreased the levels of IL-13.Increased TLR3 expression.
Animal Model:Middle cerebral artery occlusion (MCAO) model mice
Dosage:1.25 mg/kg
Administration:Intraperitoneal injection (i.p.)
Result:Reduced focal cerebral I/R injury.Increased the expression of Bcl2, Hsp27, and Hsp70, decreased Bax expression, and reduced cellular degeneration and apoptosis.Protected against cerebral ischemia and conferred protection against cerebral I/R injury through the downregulation of TLR4 signaling via TLR3.
体外研究：
Polyinosinic-polycytidylic acid (0.5-5 μg/mL, 3-24 h) 呈现剂量和时间依赖性增加诱导永生化气道上皮细胞的细胞旁通透性。Polyinosinic-polycytidylic acid (5 μg/mL, 24 h) 对 16HBE14o- 细胞没有细胞毒性。Polyinosinic-polycytidylic acid (5 μg/mL, 6 h) 在 16HBE14o- 细胞中诱导上皮顶端连接复合体和紧密连接的破坏。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备